China Resources Pharmaceutical Group Limited (China Resources Pharma) reported that every agenda item at its 12 June 2026 annual general meeting (AGM) received shareholder approval by wide margins.

Key outcomes

1. FY25 results and dividend • The audited financial statements, directors’ report and independent auditor’s report for the year ended 31 December 2025 were adopted with 99.79% support (4.93 billion shares in favour). • A final dividend of RMB0.122 per share was approved, backed by 99.99% of votes cast (4.94 billion shares).

2. Board composition • Executive directors Bai Xiaosong, Cheng Jie and Liu Changan were re-elected with support ranging from 94.66% to 99.49%. • Non-executive directors Sun Yongqiang, Wang Yuhang and Jiao Ruifang were re-elected, receiving 98.43%–99.46% approval. • Independent non-executive director Shi Luwen secured 97.12% of votes. • The board was authorised to set directors’ remuneration, gaining 99.92% support.

3. Auditor • KPMG was re-appointed as external auditor with 99.99% approval; the board is authorised to determine its fees.

4. Share mandates • Share buy-back mandate: 99.98% support (4.94 billion shares). • General issuance mandate: 92.00% support (4.54 billion shares). • Extension of the issuance mandate: 92.04% support.

Voting statistics

• Total issued shares: 6.28 billion. • All resolutions passed as ordinary resolutions; no shares were subject to mandatory abstention or special voting arrangements. • Tricor Investor Services Limited acted as scrutineer.

Attendance

Executive director Liu Changan chaired the meeting. Nine additional directors participated in person or via video conference, while three directors were absent due to business commitments.

The AGM decisions reinforce continuity in governance, confirm the FY25 financials, and grant the board broad mandates for capital management during the coming year.